articleScienceJul 18, 2024Closed access

The benefits of GLP-1 drugs beyond obesity

DJDaniel J. Drucker

Lunenfeld-Tanenbaum Research Institute

PubMed
Indexed incrossrefpubmed

Abstract

Glucagon-like peptide-1-based medicines have weight loss-independent actions.

Citation impact

140
total citations
FWCI
43.48
Percentile
100%
References
14
Citations per year

Authors

1

Topics & keywords

Topics
Keywords
  • Glucagon-like peptide-1
  • Weight loss
  • Obesity
  • Anti obesity
  • Glucagon
  • Pharmacology
  • Exenatide
  • Medicine
UN Sustainable Development Goals
  • Zero hunger
No related works found for this paper.